Allergan plc (AGN) Shares Bought by Wetherby Asset Management Inc.

Wetherby Asset Management Inc. raised its holdings in Allergan plc (NYSE:AGN) by 4.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,877 shares of the company’s stock after buying an additional 653 shares during the period. Wetherby Asset Management Inc.’s holdings in Allergan were worth $2,325,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in AGN. Nomura Holdings Inc. increased its stake in shares of Allergan by 9.2% during the fourth quarter. Nomura Holdings Inc. now owns 30,522 shares of the company’s stock worth $4,074,000 after purchasing an additional 2,580 shares during the period. American Century Companies Inc. increased its stake in shares of Allergan by 21.1% during the fourth quarter. American Century Companies Inc. now owns 1,235,389 shares of the company’s stock worth $165,122,000 after purchasing an additional 214,955 shares during the period. Institute for Wealth Management LLC. bought a new position in shares of Allergan during the fourth quarter worth approximately $716,000. Duality Advisers LP bought a new position in shares of Allergan during the fourth quarter worth approximately $13,282,000. Finally, Cetera Investment Advisers bought a new position in shares of Allergan during the first quarter worth approximately $233,000. Hedge funds and other institutional investors own 80.25% of the company’s stock.

A number of brokerages have recently weighed in on AGN. Jefferies Financial Group began coverage on Allergan in a research note on Monday, April 15th. They set a “hold” rating and a $144.95 target price on the stock. SunTrust Banks began coverage on Allergan in a research note on Tuesday, March 19th. They set a “buy” rating and a $178.00 target price on the stock. Credit Suisse Group set a $155.00 target price on Allergan and gave the stock a “hold” rating in a research note on Monday, March 25th. Raymond James reduced their price target on Allergan from $181.00 to $166.00 and set an “outperform” rating on the stock in a research report on Thursday, May 9th. Finally, Mizuho reduced their price target on Allergan to $200.00 and set a “buy” rating on the stock in a research report on Wednesday, January 30th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. Allergan currently has an average rating of “Hold” and a consensus target price of $184.52.

In other Allergan news, Chairman Brent L. Saunders bought 1,760 shares of Allergan stock in a transaction on Thursday, March 7th. The shares were purchased at an average price of $143.67 per share, with a total value of $252,859.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.08% of the company’s stock.

Shares of AGN stock traded down $1.57 during trading hours on Friday, reaching $136.47. The company’s stock had a trading volume of 21,197 shares, compared to its average volume of 2,514,701. The company has a market cap of $45.39 billion, a PE ratio of 8.18, a P/E/G ratio of 1.26 and a beta of 1.32. Allergan plc has a fifty-two week low of $125.84 and a fifty-two week high of $197.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.60 and a current ratio of 0.71.

Allergan (NYSE:AGN) last issued its earnings results on Tuesday, May 7th. The company reported $3.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.55 by $0.24. The firm had revenue of $3.60 billion for the quarter, compared to the consensus estimate of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The company’s revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.74 EPS. On average, equities analysts predict that Allergan plc will post 16.68 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Tuesday, May 14th will be issued a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.17%. The ex-dividend date is Monday, May 13th. Allergan’s dividend payout ratio is presently 17.74%.

Allergan announced that its Board of Directors has authorized a share buyback plan on Tuesday, January 29th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

WARNING: “Allergan plc (AGN) Shares Bought by Wetherby Asset Management Inc.” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2019/05/24/allergan-plc-agn-shares-bought-by-wetherby-asset-management-inc.html.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Featured Story: What is Liquidity?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.